| Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012 M Hussain, S Daignault-Newton, PW Twardowski, C Albany, MN Stein, ... Journal of Clinical Oncology 36 (10), 991, 2018 | 208 | 2018 |
| Long-term toxicity of cisplatin in germ-cell tumor survivors M Chovanec, MA Zaid, N Hanna, N El-Kouri, LH Einhorn, C Albany Annals of Oncology 28 (11), 2670-2679, 2017 | 184 | 2017 |
| Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206 N Adra, LH Einhorn, SK Althouse, NR Ammakkanavar, D Musapatika, ... Annals of Oncology 29 (1), 209-214, 2018 | 156 | 2018 |
| High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University experience N Adra, R Abonour, SK Althouse, C Albany, NH Hanna, LH Einhorn Journal of Clinical Oncology 35 (10), 1096, 2017 | 146 | 2017 |
| Extragonadal germ cell tumors: clinical presentation and management C Albany, LH Einhorn Current opinion in oncology 25 (3), 261-265, 2013 | 144 | 2013 |
| Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium S Gillessen, N Sauvé, L Collette, G Daugaard, R de Wit, C Albany, ... Journal of Clinical Oncology 39 (14), 1563-1574, 2021 | 142 | 2021 |
| Phase 2 trial of gemcitabine, cisplatin, plus ipilimumab in patients with metastatic urothelial cancer and impact of DNA damage response gene mutations on outcomes MD Galsky, H Wang, NM Hahn, P Twardowski, SK Pal, C Albany, ... European urology 73 (5), 751-759, 2018 | 123 | 2018 |
| Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist … C Albany, MJ Brames, C Fausel, CS Johnson, J Picus, LH Einhorn Journal of Clinical Oncology 30 (32), 3998-4003, 2012 | 121 | 2012 |
| Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-update consortium J Beyer, L Collette, N Sauvé, G Daugaard, DR Feldman, T Tandstad, ... Journal of clinical oncology 39 (14), 1553-1562, 2021 | 111 | 2021 |
| Brain metastases in patients with germ cell tumors: prognostic factors and treatment options—an analysis from the Global Germ Cell Cancer Group DR Feldman, A Lorch, A Kramar, C Albany, LH Einhorn, P Giannatempo, ... Journal of Clinical Oncology 34 (4), 345-351, 2016 | 105 | 2016 |
| Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation: an international collaboration P Giannatempo, GR Pond, G Sonpavde, C Albany, Y Loriot, CJ Sweeney, ... The Journal of Urology 196 (1), 95-100, 2016 | 84 | 2016 |
| Randomized, noncomparative, phase II trial of early switch from docetaxel to cabazitaxel or vice versa, with integrated biomarker analysis, in men with chemotherapy-naive … ES Antonarakis, ST Tagawa, G Galletti, D Worroll, K Ballman, ... Journal of Clinical Oncology 35 (28), 3181, 2017 | 83 | 2017 |
| Epigenetics in prostate cancer C Albany, AS Alva, AM Aparicio, R Singal, S Yellapragada, G Sonpavde, ... Prostate cancer 2011, 2011 | 79 | 2011 |
| Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors C Albany, N Adra, AC Snavely, C Cary, TA Masterson, RS Foster, ... Annals of Oncology 29 (2), 341-346, 2018 | 76 | 2018 |
| Olanzapine for the treatment of advanced cancer–related chronic nausea and/or vomiting: a randomized pilot trial RM Navari, CM Pywell, JG Le-Rademacher, P White, AB Dodge, ... JAMA oncology 6 (6), 895-899, 2020 | 71 | 2020 |
| A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN … NM Hahn, TJ Bivalacqua, AE Ross, GJ Netto, A Baras, JC Park, ... Clinical Cancer Research 23 (12), 3003-3011, 2017 | 68 | 2017 |
| Management of stage I testicular germ cell tumours M Chovanec, N Hanna, KC Cary, L Einhorn, C Albany Nature Reviews Urology 13 (11), 663-673, 2016 | 66 | 2016 |
| Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine C Albany, MP Hever-Jardine, KM von Herrmann, CY Yim, J Tam, ... Oncotarget 8 (2), 2949, 2017 | 64 | 2017 |
| Practice makes perfect: the rest of the story in testicular cancer as a model curable neoplasm T Tandstad, CK Kollmannsberger, BJ Roth, C Jeldres, S Gillessen, ... Journal of Clinical Oncology 35 (31), 3525, 2017 | 63 | 2017 |
| Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014 N Adra, SK Althouse, H Liu, MJ Brames, NH Hanna, LH Einhorn, ... Annals of Oncology 27 (5), 875-879, 2016 | 51 | 2016 |
Nabil AdraIndiana UniversityVerified email at iu.edu
